Rapivab

Biocelect is excited to announce its partnership with BioCryst Pharmaceuticals Inc. As a result Biocelect is now the exclusive distributor in Australia for Rapivab (peramivir) a neuraminidase inhibitor for the treatment of acute influenza. An exciting addition to our expanding product range.

Rapivab is the only TGA approved intravenous influenza antiviral available on the current market.